ArticleFoods (Basel, Switzerland)2026
Chemical Profiling and In Vitro Cytotoxicity Assessment of Commercial Red Yeast Rice Ingredients.
Article in Foods (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Red yeast rice (RYR) food supplements are widely used for cholesterol management due to their monacolin content, particularly monacolin K (MK), which shares the same chemical structure as lovastatin, a compound associated with several side effects. The European Food Safety Authority (EFSA) highlighted uncertainties regarding the compositional variability, characterization of bioactive constituents, and safety of RYR products, concluding that a safe level of monacolin intake could not be established. In this study, twenty-seven commercial semi-processed RYR ingredients for food supplements manufacturing were investigated through a combined chemical and biological approach to characterize their composition and evaluate potential safety concerns. Targeted LC-MS/MS analyses revealed substantial variability in MK, monacolin hydroxy acid (MKA), and dehydromonacolin K (DMK) levels among products. Exploratory qualitative untargeted metabolomics enabled the putative annotation of multiple secondary metabolites, including azaphilones and polyketides, highlighting differences in chemical profiles. Correlation analyses indicated that DMK content was associated with pigment distribution and cytotoxic responses in human hepatocellular carcinoma cells and primary human skeletal muscle cells, whereas MK and MKA showed no significant association with toxicity under the tested conditions. Exploratory proteomic profiling suggested distinct protein-abundance patterns between RYR- and simvastatin-treated cells, providing hypothesis-generating information on functional annotations associated with these patterns. These findings emphasize the importance of comprehensive chemical characterization and quality control strategies considering both monacolins and secondary metabolites to improve the safety assessment of RYR supplements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.